TickerFacts.

Q/C Technologies, Inc. (QCLS): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$9.07M
Year ended 2025-12-31
-$9.47M
Trailing 12 months to 2026-06-30
2013-12-31: -$2.73M2014-12-31: -$3.88M2015-12-31: -$5.13M2016-12-31: -$4.17M2017-12-31: -$5.08M2018-12-31: -$8.50M2019-12-31: -$3.07M2020-12-31: -$4.66M2021-12-31: -$19.52M2022-12-31: -$12.27M2023-12-31: -$12.98M2024-12-31: -$8.98M2025-12-31: -$9.07M-$9.07M
2013-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31-$9.07Mn/m2026-04-15, From 2025-01-01
2024-12-31-$8.98Mn/m2026-04-15, From 2024-01-01
2023-12-31-$12.98Mn/m2025-04-11, From 2023-01-01
2022-12-31-$12.27Mn/m2024-04-01, From 2022-01-01
2021-12-31-$19.52Mn/m2023-03-31, From 2021-01-01
2020-12-31-$4.66Mn/m2022-03-31, From 2020-01-01
2019-12-31-$3.07Mn/m2021-03-01, From 2019-01-01
2018-12-31-$8.50Mn/m2020-03-25, From 2018-01-01
2017-12-31-$5.08Mn/m2019-04-01, From 2017-01-01
2016-12-31-$4.17Mn/m2018-07-13, From 2016-01-01
2015-12-31-$5.13Mn/m2017-04-11, From 2015-01-01
2014-12-31-$3.88Mn/m2016-03-30, From 2014-01-01
2013-12-31-$2.73Mn/a2015-03-23, From 2013-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Q/C Technologies, Inc. (QCLS)2025-12-31-$9.07Mn/m
Achieve Life Sciences, Inc. (ACHV)2025-12-31-$49.47Mn/m
Immucell Corp (ICCC)2025-12-31$2.48M+591.6%
Anbio Biotechnology (NNNN)2025-12-31-$6.74Mn/m
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31-$22.18Mn/m
Alpha Teknova, Inc. (TKNO)2025-12-31-$8.65Mn/m
Cardio Diagnostics Holdings, Inc. (CDIO)2025-12-31-$5.73Mn/m
Volitionrx Ltd (VNRX)2025-12-31-$19.68Mn/m
Biomerica Inc (BMRA)2026-05-31-$3.42Mn/m

Compare QCLS, ACHV, ICCC, NNNN side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗